Asparaginase Escherichia coli-derived - EUSA Pharma

Drug Profile

Asparaginase Escherichia coli-derived - EUSA Pharma

Alternative Names: E. coli L-asparaginase; Kidrolase; L-asparaginase

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator EUSA Pharma
  • Class Amidohydrolases; Antineoplastics
  • Mechanism of Action Asparagine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia; Lymphomatous meningitis; Non-Hodgkin's lymphoma

Most Recent Events

  • 30 Sep 2015 Biomarkers information updated
  • 12 Jun 2012 EUSA Pharma has been acquired by Jazz Pharmaceuticals plc
  • 01 Dec 2010 Launched for Acute lymphoblastic leukaemia in Algeria before 2011 (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top